Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Therapeutic targeting of KDM1A/LSD1 in Ewing sarcoma with SP-2509 engages the endoplasmic reticulum stress response.

Pishas KI, Drenberg CD, Taslim C, Theisen ER, Johnson KM, Saund RS, Pop IL, Crompton BD, Lawlor ER, Tirode F, Mora J, Delattre O, Beckerle MC, Callen DF, Sharma S, Lessnick SL.

Mol Cancer Ther. 2018 Jul 11. pii: molcanther.0373.2018. doi: 10.1158/1535-7163.MCT-18-0373. [Epub ahead of print]

PMID:
29997151
2.

Author Correction: EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.

Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, Iniguez AB, Bernard X, Masamsetti VP, Roston S, Lawlor ER, Toretsky JA, Stegmaier K, Lessnick SL, Chen Y, Bishop AJR.

Nature. 2018 Jun 27. doi: 10.1038/s41586-018-0230-z. [Epub ahead of print]

PMID:
29950716
3.

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts.

Thomas TT, Chukkapalli S, Van Noord RA, Krook M, Hoenerhoff MJ, Dillman JR, Lawlor ER, Opipari VP, Newman EA.

J Vis Exp. 2018 May 25;(135). doi: 10.3791/57558.

PMID:
29889191
4.

The effect of community-based interventions for cardiovascular disease secondary prevention on behavioural risk factors.

Lawlor ER, Bradley DT, Cupples ME, Tully MA.

Prev Med. 2018 May 24;114:24-38. doi: 10.1016/j.ypmed.2018.05.019. [Epub ahead of print] Review.

PMID:
29802876
5.

Menin regulates the serine biosynthetic pathway in Ewing sarcoma.

Svoboda LK, Teh SSK, Sud S, Kerk S, Zebolsky A, Treichel S, Thomas D, Halbrook CJ, Lee HJ, Kremer D, Zhang L, Klossowski S, Bankhead AR, Magnuson B, Ljungman M, Cierpicki T, Grembecka J, Lyssiotis CA, Lawlor ER.

J Pathol. 2018 Jul;245(3):324-336. doi: 10.1002/path.5085. Epub 2018 May 28.

PMID:
29672864
6.

EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.

Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, Iniguez AB, Bernard X, Masamsetti VP, Roston S, Lawlor ER, Toretsky JA, Stegmaier K, Lessnick SL, Chen Y, Bishop AJR.

Nature. 2018 Mar 15;555(7696):387-391. doi: 10.1038/nature25748. Epub 2018 Mar 7. Erratum in: Nature. 2018 Jun 27;:.

PMID:
29513652
7.

The Ewing Sarcoma Secretome and Its Response to Activation of Wnt/beta-catenin Signaling.

Hawkins AG, Basrur V, da Veiga Leprevost F, Pedersen E, Sperring C, Nesvizhskii AI, Lawlor ER.

Mol Cell Proteomics. 2018 May;17(5):901-912. doi: 10.1074/mcp.RA118.000596. Epub 2018 Jan 31.

PMID:
29386236
8.

Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.

Newman EA, Chukkapalli S, Bashllari D, Thomas TT, Van Noord RA, Lawlor ER, Hoenerhoff MJ, Opipari AW, Opipari VP.

Cell Death Dis. 2017 Dec 13;8(12):3208. doi: 10.1038/s41419-017-0004-9.

9.

Tissue-directed Implantation Using Ultrasound Visualization for Development of Biologically Relevant Metastatic Tumor Xenografts.

VAN Noord RA, Thomas T, Krook M, Chukkapalli S, Hoenerhoff MJ, Dillman JR, Lawlor ER, Opipari VP, Newman EA.

In Vivo. 2017 Sep-Oct;31(5):779-791.

10.

Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.

Svoboda LK, Bailey N, Van Noord RA, Krook MA, Harris A, Cramer C, Jasman B, Patel RM, Thomas D, Borkin D, Cierpicki T, Grembecka J, Lawlor ER.

Oncotarget. 2017 Jan 3;8(1):458-471. doi: 10.18632/oncotarget.13444.

11.

Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma.

Haak AJ, Appleton KM, Lisabeth EM, Misek SA, Ji Y, Wade SM, Bell JL, Rockwell CE, Airik M, Krook MA, Larsen SD, Verhaegen M, Lawlor ER, Neubig RR.

Mol Cancer Ther. 2017 Jan;16(1):193-204. doi: 10.1158/1535-7163.MCT-16-0482. Epub 2016 Nov 11.

12.

BMI1 regulates PRC1 architecture and activity through homo- and hetero-oligomerization.

Gray F, Cho HJ, Shukla S, He S, Harris A, Boytsov B, Jaremko Ł, Jaremko M, Demeler B, Lawlor ER, Grembecka J, Cierpicki T.

Nat Commun. 2016 Nov 9;7:13343. doi: 10.1038/ncomms13343.

13.

Small-Molecule Inhibition of Rho/MKL/SRF Transcription in Prostate Cancer Cells: Modulation of Cell Cycle, ER Stress, and Metastasis Gene Networks.

Evelyn CR, Lisabeth EM, Wade SM, Haak AJ, Johnson CN, Lawlor ER, Neubig RR.

Microarrays (Basel). 2016 May 28;5(2). pii: E13. doi: 10.3390/microarrays5020013.

14.

Micro-Environmental Stress Induces Src-Dependent Activation of Invadopodia and Cell Migration in Ewing Sarcoma.

Bailey KM, Airik M, Krook MA, Pedersen EA, Lawlor ER.

Neoplasia. 2016 Aug;18(8):480-8. doi: 10.1016/j.neo.2016.06.008.

15.

A bivalent promoter contributes to stress-induced plasticity of CXCR4 in Ewing sarcoma.

Krook MA, Hawkins AG, Patel RM, Lucas DR, Van Noord R, Chugh R, Lawlor ER.

Oncotarget. 2016 Sep 20;7(38):61775-61788. doi: 10.18632/oncotarget.11240.

16.

Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States.

Pedersen EA, Menon R, Bailey KM, Thomas DG, Van Noord RA, Tran J, Wang H, Qu PP, Hoering A, Fearon ER, Chugh R, Lawlor ER.

Cancer Res. 2016 Sep 1;76(17):5040-53. doi: 10.1158/0008-5472.CAN-15-3422. Epub 2016 Jun 30.

17.

The posterior HOXD locus: Its contribution to phenotype and malignancy of Ewing sarcoma.

von Heyking K, Roth L, Ertl M, Schmidt O, Calzada-Wack J, Neff F, Lawlor ER, Burdach S, Richter GH.

Oncotarget. 2016 Jul 5;7(27):41767-41780. doi: 10.18632/oncotarget.9702.

18.

Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group.

Cash T, McIlvaine E, Krailo MD, Lessnick SL, Lawlor ER, Laack N, Sorger J, Marina N, Grier HE, Granowetter L, Womer RB, DuBois SG.

Pediatr Blood Cancer. 2016 Oct;63(10):1771-9. doi: 10.1002/pbc.26096. Epub 2016 Jun 14.

19.

Promoter Methylation Analysis Reveals That KCNA5 Ion Channel Silencing Supports Ewing Sarcoma Cell Proliferation.

Ryland KE, Hawkins AG, Weisenberger DJ, Punj V, Borinstein SC, Laird PW, Martens JR, Lawlor ER.

Mol Cancer Res. 2016 Jan;14(1):26-34. doi: 10.1158/1541-7786.MCR-15-0343. Epub 2015 Nov 16.

20.

Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?

Lawlor ER, Sorensen PH.

Crit Rev Oncog. 2015;20(3-4):155-71. Review.

21.

Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group.

Volchenboum SL, Andrade J, Huang L, Barkauskas DA, Krailo M, Womer RB, Ranft A, Potratz J, Dirksen U, Triche TJ, Lawlor ER.

J Pathol Clin Res. 2015 Apr;1(2):83-94.

22.

Deficiency for the cysteine protease cathepsin L impairs Myc-induced tumorigenesis in a mouse model of pancreatic neuroendocrine cancer.

Brindle NR, Joyce JA, Rostker F, Lawlor ER, Swigart-Brown L, Evan G, Hanahan D, Shchors K.

PLoS One. 2015 Apr 30;10(4):e0120348. doi: 10.1371/journal.pone.0120348. eCollection 2015.

23.

Use of an employment advisory service by cancer survivors.

Lawlor ER, Donnelly M.

J Psychosoc Oncol. 2015;33(3):219-31. doi: 10.1080/07347332.2015.1019658.

PMID:
25761149
24.

Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.

Selvanathan SP, Graham GT, Erkizan HV, Dirksen U, Natarajan TG, Dakic A, Yu S, Liu X, Paulsen MT, Ljungman ME, Wu CH, Lawlor ER, Üren A, Toretsky JA.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1307-16. doi: 10.1073/pnas.1500536112. Epub 2015 Mar 3.

25.

Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.

Svoboda LK, Harris A, Bailey NJ, Schwentner R, Tomazou E, von Levetzow C, Magnuson B, Ljungman M, Kovar H, Lawlor ER.

Epigenetics. 2014 Dec;9(12):1613-25. doi: 10.4161/15592294.2014.988048.

26.

Polycomb-dependent repression of the potassium channel-encoding gene KCNA5 promotes cancer cell survival under conditions of stress.

Ryland KE, Svoboda LK, Vesely ED, McIntyre JC, Zhang L, Martens JR, Lawlor ER.

Oncogene. 2015 Aug 27;34(35):4591-600. doi: 10.1038/onc.2014.384. Epub 2014 Dec 1.

27.

Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.

Tilan JU, Krailo M, Barkauskas DA, Galli S, Mtaweh H, Long J, Wang H, Hawkins K, Lu C, Jeha D, Izycka-Swieszewska E, Lawlor ER, Toretsky JA, Kitlinska JB.

Cancer. 2015 Mar 1;121(5):697-707. doi: 10.1002/cncr.29090. Epub 2014 Nov 11.

28.

Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma.

Ban J, Aryee DN, Fourtouna A, van der Ent W, Kauer M, Niedan S, Machado I, Rodriguez-Galindo C, Tirado OM, Schwentner R, Picci P, Flanagan AM, Berg V, Strauss SJ, Scotlandi K, Lawlor ER, Snaar-Jagalska E, Llombart-Bosch A, Kovar H.

Cancer Res. 2014 Nov 15;74(22):6578-88. doi: 10.1158/0008-5472.CAN-14-1736. Epub 2014 Oct 3.

29.

Clinical and biochemical function of polymorphic NR0B1 GGAA-microsatellites in Ewing sarcoma: a report from the Children's Oncology Group.

Monument MJ, Johnson KM, McIlvaine E, Abegglen L, Watkins WS, Jorde LB, Womer RB, Beeler N, Monovich L, Lawlor ER, Bridge JA, Schiffman JD, Krailo MD, Randall RL, Lessnick SL.

PLoS One. 2014 Aug 5;9(8):e104378. doi: 10.1371/journal.pone.0104378. eCollection 2014.

30.

Differentially expressed miRNAs in Ewing sarcoma compared to mesenchymal stem cells: low miR-31 expression with effects on proliferation and invasion.

Karnuth B, Dedy N, Spieker T, Lawlor ER, Gattenlöhner S, Ranft A, Dirksen U, Jürgens H, Bräuninger A.

PLoS One. 2014 Mar 25;9(3):e93067. doi: 10.1371/journal.pone.0093067. eCollection 2014.

31.

Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma.

Krook MA, Nicholls LA, Scannell CA, Chugh R, Thomas DG, Lawlor ER.

Mol Cancer Res. 2014 Jun;12(6):953-64. doi: 10.1158/1541-7786.MCR-13-0668. Epub 2014 Mar 20.

32.

Comparative evaluation of strategies for quantifying signaling pathway proteins in Ewing sarcoma.

Applebaum MA, Thomas DG, Hembrough T, Burrows J, Horvai AE, Lawlor ER, DuBois SG.

Appl Immunohistochem Mol Morphol. 2014 Sep;22(8):593-9. doi: 10.1097/PAI.0b013e3182a8d4bb.

33.

Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines.

May WA, Grigoryan RS, Keshelava N, Cabral DJ, Christensen LL, Jenabi J, Ji L, Triche TJ, Lawlor ER, Reynolds CP.

PLoS One. 2013 Dec 2;8(12):e80060. doi: 10.1371/journal.pone.0080060. eCollection 2013.

34.

A comprehensive promoter landscape identifies a novel promoter for CD133 in restricted tissues, cancers, and stem cells.

Sompallae R, Hofmann O, Maher CA, Gedye C, Behren A, Vitezic M, Daub CO, Devalle S, Caballero OL, Carninci P, Hayashizaki Y, Lawlor ER, Cebon J, Hide W.

Front Genet. 2013 Oct 29;4:209. doi: 10.3389/fgene.2013.00209. eCollection 2013.

35.

Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.

Shukla N, Schiffman J, Reed D, Davis IJ, Womer RB, Lessnick SL, Lawlor ER; COG Ewing Sarcoma Biology Committee.

Front Oncol. 2013 Jun 6;3:141. doi: 10.3389/fonc.2013.00141. eCollection 2013.

36.

LGR5 is Expressed by Ewing Sarcoma and Potentiates Wnt/β-Catenin Signaling.

Scannell CA, Pedersen EA, Mosher JT, Krook MA, Nicholls LA, Wilky BA, Loeb DM, Lawlor ER.

Front Oncol. 2013 Apr 15;3:81. doi: 10.3389/fonc.2013.00081. eCollection 2013.

37.

A Decade in Banking Ewing Sarcoma: A Report from the Children's Oncology Group.

Borinstein SC, Beeler N, Block JJ, Gorlick R, Grohar P, Jedlicka P, Krailo M, Morris C, Phillips S, Siegal GP, Lawlor ER, Lessnick SL; COG Ewing Sarcoma Biology Committee.

Front Oncol. 2013 Mar 20;3:57. doi: 10.3389/fonc.2013.00057. eCollection 2013.

38.

Ewing sarcoma of the kidney: case series and literature review of an often overlooked entity in the diagnosis of primary renal tumors.

Rowe RG, Thomas DG, Schuetze SM, Hafez KS, Lawlor ER, Chugh R.

Urology. 2013 Feb;81(2):347-53. doi: 10.1016/j.urology.2012.10.016. Review.

PMID:
23374800
39.

DNA methylation and gene expression profiling of ewing sarcoma primary tumors reveal genes that are potential targets of epigenetic inactivation.

Patel N, Black J, Chen X, Marcondes AM, Grady WM, Lawlor ER, Borinstein SC.

Sarcoma. 2012;2012:498472. Epub 2012 Sep 12.

40.

The first European interdisciplinary ewing sarcoma research summit.

Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PC, Kontny U, Lawlor ER, Lessnick SL, Llombart-Bosch A, Metzler M, Moriggl R, Niedan S, Potratz J, Redini F, Richter GH, Riedmann LT, Rossig C, Schäfer BW, Schwentner R, Scotlandi K, Sorensen PH, Staege MS, Tirode F, Toretsky J, Ventura S, Eggert A, Ladenstein R.

Front Oncol. 2012 May 29;2:54. doi: 10.3389/fonc.2012.00054. eCollection 2012.

41.

Epigenetic changes in pediatric solid tumors: promising new targets.

Lawlor ER, Thiele CJ.

Clin Cancer Res. 2012 May 15;18(10):2768-79. doi: 10.1158/1078-0432.CCR-11-1921. Review.

42.

Modeling initiation of Ewing sarcoma in human neural crest cells.

von Levetzow C, Jiang X, Gwye Y, von Levetzow G, Hung L, Cooper A, Hsu JH, Lawlor ER.

PLoS One. 2011 Apr 29;6(4):e19305. doi: 10.1371/journal.pone.0019305.

43.

BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma.

Hsu JH, Lawlor ER.

Oncogene. 2011 Apr 28;30(17):2077-85. doi: 10.1038/onc.2010.571. Epub 2010 Dec 20.

44.

Ewing tumors that do not overexpress BMI-1 are a distinct molecular subclass with variant biology: a report from the Children's Oncology Group.

Cooper A, van Doorninck J, Ji L, Russell D, Ladanyi M, Shimada H, Krailo M, Womer RB, Hsu JH, Thomas D, Triche TJ, Sposto R, Lawlor ER.

Clin Cancer Res. 2011 Jan 1;17(1):56-66. doi: 10.1158/1078-0432.CCR-10-1417. Epub 2010 Nov 3.

45.

Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing's sarcoma.

Bennani-Baiti IM, Cooper A, Lawlor ER, Kauer M, Ban J, Aryee DN, Kovar H.

Clin Cancer Res. 2010 Jul 15;16(14):3769-78. doi: 10.1158/1078-0432.CCR-10-0558. Epub 2010 Jun 4.

46.

CD133 expression in chemo-resistant Ewing sarcoma cells.

Jiang X, Gwye Y, Russell D, Cao C, Douglas D, Hung L, Kovar H, Triche TJ, Lawlor ER.

BMC Cancer. 2010 Mar 26;10:116. doi: 10.1186/1471-2407-10-116.

47.

Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group.

van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, Krailo MD, Lessnick SL, Marina N, Triche TJ, Sposto R, Womer RB, Lawlor ER.

J Clin Oncol. 2010 Apr 20;28(12):1989-94. doi: 10.1200/JCO.2009.24.5845. Epub 2010 Mar 22.

48.

Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.

Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S, Wai D, Lawlor ER, Triche TJ, Pallen CJ, Dunn SE.

Mol Cancer Ther. 2009 Nov;8(11):3024-35. doi: 10.1158/1535-7163.MCT-09-0365. Epub 2009 Nov 3.

49.

GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors.

Joo J, Christensen L, Warner K, States L, Kang HG, Vo K, Lawlor ER, May WA.

PLoS One. 2009 Oct 27;4(10):e7608. doi: 10.1371/journal.pone.0007608.

50.

Isolation and characterization of neural crest stem cells derived from in vitro-differentiated human embryonic stem cells.

Jiang X, Gwye Y, McKeown SJ, Bronner-Fraser M, Lutzko C, Lawlor ER.

Stem Cells Dev. 2009 Sep;18(7):1059-70. doi: 10.1089/scd.2008.0362.

Supplemental Content

Loading ...
Support Center